TEAM (Thiotepa, Etoposide, Cytosar, Melphalan ) for AutoSCT in Lymphoma

Phase 2
Completed
Conditions
Interventions
Registration Number
NCT03346096
Lead Sponsor
Sheba Medical Center
Brief Summary

Study is designed to explore whether the introduction of Thiotepa, to the pre autologous stem-cell transplantation (ASCT) conditioning will reduce toxicity and thus improve outcome following transplantation in up to 24 patients with malignant lymphoma including both non-Hodgkin's lymphoma (NHL) and Hodgkin's lymphoma ( HL) improving toxicity profile , reduci...

Detailed Description

Not available

Recruitment & Eligibility

Status
COMPLETED
Sex
All
Target Recruitment
50
Inclusion Criteria
  1. Patients with non-Hodgkin's and Hodgkin's lymphoma as confirmed by a pathological biopsy report.
  2. Patients who are candidates for Autologous stem-cell transplantation due to refractory or relapsing disease by standard institutional indications and comply with standard transplant eligibility criteria.
  3. Age less than physiologic 70 years.
  4. Patients with an adequate autologous stem cell collection for transplantation and backup (>5 x 106 CD34(cluster of differentiation 34)+ cells/kg) .Patients must sign written informed consent.
  5. No limitation on bulky disease or bone marrow involvement. No limitation on the number and response to prior therapy. Prior autologous transplantation and/or treatment with rituximab allowed. All prior chemotherapy completed at least three weeks before study treatment
Read More
Exclusion Criteria
  1. Bilirubin > 3.0 mg/dl, transaminases > 3 times upper normal limit
  2. Creatinine > 2.0 mg/dl
  3. Eastern Cooperative Oncology Group (ECOG) Performance status > 2
  4. Uncontrolled infection
  5. Pregnancy or lactation
  6. Abnormal lung diffusion capacity (DLCO < 40% predicted)
  7. Severe cardiovascular disease
  8. CNS (central nervous system) disease involvement
  9. Pleural effusion or ascites > 1 liter
  10. Psychiatric conditions/disease that impair the ability to give informed consent or to adequately co-operate
Read More

Study & Design

Study Type
INTERVENTIONAL
Study Design
SINGLE_GROUP
Arm && Interventions
GroupInterventionDescription
ThiotepaThiotepaThiotepa for reduce toxicity and improve outcome following transplantation
Primary Outcome Measures
NameTimeMethod
Toxicities graded by Bearman's criteria and infectious complications15 month

To determine the relative toxicity and response rate of TEAM preparative regimen pre- Autologous stem cell transplantation in patients with non-Hodgkin's and Hodgkin's Lymphoma

Secondary Outcome Measures
NameTimeMethod

Trial Locations

Locations (1)

Chaim Sheba Medical Center

🇮🇱

Ramat Gan, Israel

© Copyright 2024. All Rights Reserved by MedPath